Patients as Key Partners in Rare Disease Drug Development July 22, 2016 Share this page As the technology to produce these complex therapeutics has matured, many more ADCs have been approved or are in late-phase clinical trials. Related Articles The EveryLife Foundation Submits Comments to Support Patient-Focused Drug Development and Medical Innovation July 01, 2026 FDA Rare Disease Roundtable – June 3, 2026 June 04, 2026 EveryLife Foundation Highlights Rare Disease Regulatory Recommendations and the Community’s Eagerness to Work with FDA’s New Leadership May 29, 2026 See All News